Healthcare · Drug Manufacturers Specialty Generic · NASDAQ
Pacira BioSciences (PCRX) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $1.46B, a trailing price-to-earnings ratio of 14.0 and a free-cash-flow yield of 8.3%. Over the most recent reported fiscal year, revenue grew 3.6% and free cash flow per share fell 21.5%. Nama's AI scorecard rates it Buy, 7.2 out of 10.
AI scorecard
Buy · 7.2/10
Clearly positive, short of the top band. As of Nov 20, 2026.
Shariah screen
Not Shariah Compliant
At least one of the three ratios or the industry test failed.
Off its high
-55.6%
How far the last close sits under the highest price of the past five years.
Market cap
$1.46B
Trailing P/E
14.0
Price / book
2.0
Price / sales
2.0
FCF yield
8.3%
Dividend yield
—
Gross margin
78.7%
Operating margin
3.0%
Net margin
5.1%
Revenue growth (YoY)
+3.6%
Revenue growth (3-yr annual)
+2.9%
EPS growth (YoY)
-18.1%
FCF/share growth (YoY)
-21.5%
Beta
0.2
Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers Specialty Generic
PCRX earnings
Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.91).
Beat the EPS estimate in 3 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 5, 2026
$0.70
$0.15
+366.7%
$176.65M
Q2 2026
Aug 4, 2026
$0.73
$0.65
+12.3%
$192.40M
Q1 2026
Apr 30, 2026
$0.60
$0.56
+7.1%
$177.38M
Q4 2025
Feb 26, 2026
$0.57
$0.90
-36.7%
$196.87M
PCRX analyst price target
Median target $36.50 from 6 analysts, ranging $28.00 – $36.50.
Nama's AI scorecard currently rates Pacira BioSciences Buy (7.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PCRX's P/E ratio?
Pacira BioSciences trades at a trailing price-to-earnings ratio of 14.0.
When does PCRX report earnings?
Pacira BioSciences's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.91.
What is the PCRX price target?
The median analyst price target from 6 analysts is $36.50, with a range of $28.00 – $36.50.
Is PCRX Shariah compliant?
Nama's AAOIFI-style screen reads Pacira BioSciences as Not Shariah Compliant. At least one of the three ratios or the industry test failed.